MindMed Appoints Matt Wiley as Chief Commercial Officer

LOS ANGELES-Mind Medicine (MindMed) Inc. a biopharmaceutical company specializing in brain health disorders, has announced the appointment of Matt Wiley as Chief Commercial Officer (CCO). ​

In his new role, Mr. Wiley will oversee MindMed’s commercial strategy, particularly in preparation for the potential launch of MM120, an orally disintegrating tablet targeting generalized anxiety disorder (GAD) and major depressive disorder (MDD).

Mr. Wiley brings over 25 years of experience in sales, marketing, and strategic leadership across multiple specialty product launches. Prior to joining MindMed, he served as CCO at BioXcel Therapeutics, overseeing the launch of treatments for agitation associated with schizophrenia and bipolar disorder. His previous roles include CCO at VYNE Therapeutics and Vice President of Marketing at Jazz Pharmaceuticals, where he contributed to the commercial success of treatments for narcolepsy and sleep apnea. ​ed, stated that Mr. Wiley’s experience in launching neuroscience and psychiatric therapeutics will be valuable as the company prepares for potential FDA approval of MM120. ​

Mr. Wiley expressed enthusiasm about joining MindMed, highlighting MM120’s potential as a transformative therapy for anxiety and depression. ​

In connection with his appointment, Mr. Wiley received inducement awards comprising an option to purchase 350,000 common shares and 125,000 performance stock units, subject to performance metrics and continued employment. ​

MindMed is developing a pipeline of innovative product candidates targeting neurotransmitter pathways involved in brain health. The company trades on NASDAQ under the symbol MNMD.